{"id":"W3200553460","doi":"10.1016/j.kint.2021.05.015","title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","year":2021,"lang":"en","type":"article","venue":"Kidney International","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":791,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Impact; McMaster University; University of Toronto","funders":"Medical Research Council; Chugai Pharmaceutical; EMD Serono; MorphoSys; Astellas Pharma; Idorsia Pharmaceuticals; ZonMw; CSL Behring; National Institute for Health and Care Research; Bristol-Myers Squibb; University of Leicester; Argenx; National Institutes of Health; Société de Néphrologie; Natera; Genentech; Amicus Therapeutics; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Omeros Corporation; Celgene; BioCryst; Prothena; Alnylam Pharmaceuticals; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; InflaRx; Pfizer; Biogen; University Health Network; GlaxoSmithKline; American Society of Nephrology; AstraZeneca; Amgen","keywords":"Guideline; Medicine; Intensive care medicine; Lupus nephritis; Glomerulonephritis; Focal segmental glomerulosclerosis; Nephropathy; Immunology; Disease; Pathology; Internal medicine; Kidney; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006460814,0.001496664,0.002800508,0.004171268,0.0006632654,0.003072896,0.00339032,0.003858407,0.01344215],"category_scores_gemma":[0.02060929,0.0006840175,0.002355773,0.004978406,0.0006060122,0.001586113,0.001307021,0.005764989,0.0131818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003317739,"about_ca_system_score_gemma":0.01329971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02859553,"about_ca_topic_score_gemma":0.0315721,"domain_scores_codex":[0.9949189,0.00157004,0.001078474,0.0002162666,0.00180775,0.0004085425],"domain_scores_gemma":[0.9798245,0.003369509,0.002534603,0.0002202621,0.01276472,0.001286368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008421521,0.00004321336,0.0005560691,0.001748306,0.00005716673,0.00007418682,0.00003282599,0.0002606499,0.00008780755,0.001083107,0.9304866,0.06548589],"study_design_scores_gemma":[0.0002281792,0.00008633822,0.00545116,0.0127163,0.0002408546,0.0003188055,0.00008285648,0.0003296694,0.0001674619,0.001735594,0.9785981,0.00004475496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.002624237,0.3596816,0.01146197,0.3424396,0.05170602,0.00330301,0.0952485,0.00138629,0.1321488],"genre_scores_gemma":[0.01868695,0.4148958,0.04691822,0.1837726,0.04125401,0.006658707,0.2156721,0.0009525398,0.0711891],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02859553,"threshold_uncertainty_score":0.05685818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0112387636961169,"score_gpt":0.2881005084737354,"score_spread":0.2768617447776185,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}